Industry
Biotechnology
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:25 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 8:02 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 11:41 am
Portfolio Pulse from Benzinga Insights
May 31, 2024 | 1:00 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 9:58 am
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 10:40 am
Portfolio Pulse from Benzinga Newsdesk
May 21, 2024 | 8:34 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.